Reducing the frequency and severity of auditory hallucinations: the AVATAR clinical trial

ISRCTN ISRCTN65314790
DOI https://doi.org/10.1186/ISRCTN65314790
Secondary identifying numbers 1
Submission date
15/03/2013
Registration date
27/03/2013
Last edited
25/05/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
The experience of distressing voices that persist despite medical treatment is a serious problem for many patients suffering from severe mental health problems. Avatar therapy is a new computer-assisted therapy that has shown some benefit in a small pilot study. The aim of this study is to test whether avatar therapy is more effective than supportive counselling.

Who can participate?
Anyone aged over 18 who has experienced voices speaking in English that have persisted for at least 12 months despite medical treatment.

What does the study involve?
After consenting to take part, participants are asked questions about the voices they hear, their mental and physical health and how the voices affect their quality of life. Participants are then randomly allocated to either avatar therapy or supportive counselling. Participants allocated to the avatar therapy are helped to use a computer program to develop an 'avatar' (image and voice) similar to the person or entity whose voice bothers them. The therapist uses this avatar in the therapy sessions to talk with them and help them to practice ways of coping with the voices. Participants allocated to supportive counselling do not create or use the avatar but talk with the therapist about the voice, their everyday life and how they are feeling more generally. Both types of treatment are given over six sessions of a half-hour each. All treatment sessions are recorded and participants are given these recordings on a small MP3 player to take away to use on their own at any time. After the six therapy sessions a researcher asks them the same questions they were asked before they started therapy. Participants are contacted again at 12 weeks and 6 months from when they joined the study to see whether any improvement has continued. Participants also provide their views about the therapy and how it may be improved in future.

What are the possible benefits and risks of participating?
The possible benefits are reductions in the frequency, severity and distress caused by the voices. The risks are that the treatment may be distressing and may not be effective.

Where is the study run from?
Clinics in the South London and Maudsley NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
June 2013 to June 2016

Who is funding the study?
Wellcome Trust (UK)

Who is the main contact?
Prof. Thomas J Craig
Thomas.Craig@kcl.ac.uk

Contact information

Prof Thomas Jamieson Craig
Scientific

PO 33 HSPRD
Institute of Psychiatry
De Crespigny Park
London
SE5 8AF
United Kingdom

Email thomas.craig@kcl.ac.uk

Study information

Study designSingle-centre pragmatic two-arm observer-blind randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleReducing the frequency and severity of auditory hallucinations: a randomised clinical trial of a novel Audio-Visual Assisted Therapy Aid for Refractory auditory hallucinations (AVATAR) compared to supportive counselling
Study acronymAVATAR
Study objectivesAVATAR therapy will result in a greater decrease in the frequency and subjective severity of auditory hallucinations than is achieved by supportive counselling.
Ethics approval(s)NRES Committee London - Hampstead, 26/04/2013, REC ref: 13/LO/0482
Health condition(s) or problem(s) studiedSevere mental illness
Intervention1. AVATAR therapy: an average of 6 x ½ hour weekly sessions
2. CONTROL therapy: supportive counselling also for 6 x ½ hour weekly sessions
Six sessions of a half an hour each, once per week
Intervention typeOther
Primary outcome measureCurrent primary outcome measures as of 21/09/2017:
Total score on the auditory hallucinations component of the Psychotic Symptoms Rating Scale PSYRATS-AH (Haddock et al., 1999), measured at baseline, 12 weeks and 6 months

Previous primary outcome measures:
Total score on the auditory hallucinations component of the Psychotic Symptoms Rating Scale PSYRATS-AH (Haddock et al., 1999), measured at baseline, 8 weeks, 12 weeks and 6 months
Secondary outcome measuresCurrent secondary outcome measures as of 21/09/2017:

Voices outcomes:
1. Beliefs about Voices Revised BAVQ-R (Chadwicket al., 2000)
2. Voices Acceptance and Actions Scale (Shawyer et al., 2007)
3. Voice power differential scale (Birchwood et al., 2000)

Global:
1. Scales for the Assessment of Positive and Negative Symptoms (SAPS/SANS - Andreasen,1984)
2. Psychotic Symptoms Rating Scale- Delusions (Haddock et al., 1999)
3. Modified Illness Perceptions Questionnaire (Watson et al 2006, Marcus et al 2014)
4. Calgary Depression Scale (Addington et al., 1993)

Quality of life:
1. Manchester Short Assessment of Quality of Life - MANSA (Priebe et al., 1999)
2. EQ5-D (EuroQol, 1999)

Service use:
Client service receipt inventory (Beecham and Knapp, 2001)

Measured at baseline, 12 weeks and 6 months

Previous secondary outcome measures:

Voices outcomes:
1. Beliefs about Voices Revised BAVQ-R (Chadwicket al., 2000)
2. Voices Acceptance and Actions Scale (Shawyer et al., 2007)
3. Voice power differential scale (Birchwood et al., 2000)

Global:
1. Scales for the Assessment of Positive and Negative Symptoms (SAPS/SANS - Andreasen,1984)
2. Psychotic Symptoms Rating Scale- Delusions (Haddock et al., 1999)
3. Beliefs about problems (Watson et al., 2006)
4. Calgary Depression Scale (Addington et al., 1993)

Quality of life:
1. Manchester Short Assessment of Quality of Life - MANSA (Priebe et al., 1999)
2. EQ5-D (EuroQol, 1999)

Service use:
Client service receipt inventory (Beecham and Knapp, 2001)

Measured at baseline, 8 weeks, 12 weeks and 6 months
Overall study start date01/06/2013
Completion date01/06/2016

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants142
Total final enrolment150
Key inclusion criteriaMale or female, aged 18+ who have experienced persistent auditory hallucinations despite medical treatment
Key exclusion criteria1. Age under 18
2. Primary diagnosis of organic brain disease or substance dependency
3. Auditory hallucinations in a language not spoken by therapists
Date of first enrolment01/06/2013
Date of final enrolment01/06/2016

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

PO 33 HSPRD
London
SE5 8AF
United Kingdom

Sponsor information

King's College London (UK)
University/education

c/o Keith Brennan
Director of Research Management
Room 1.8 Hodgkin Building
Guys Campus
King's College London
London
SE1 4UL
England
United Kingdom

Website http://www.kcl.ac.uk
ROR logo "ROR" https://ror.org/0220mzb33

Funders

Funder type

Charity

Wellcome Trust (UK), FWBC-AVATAR 098272/z/12/z
Private sector organisation / International organizations
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planPlanned publication in a high-impact peer reviewed journal.
IPD sharing planThe data sharing plans for the current study are unknown and will be made available at a later date.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 13/08/2015 Yes No
Results article results 01/01/2018 Yes No
Other publications participant experiences 24/05/2022 25/05/2022 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

25/05/2022: The following changes have been made:
1. Publication reference added.
2. The total final enrolment number has been added from the 2018 reference.
13/12/2017: Internal review.
28/11/2017: Publication reference added.
21/09/2017: Publication and dissemination plan and IPD sharing statement added.